| scholarly article | Q13442814 |
| P50 | author | Alain Bouckenooghe | Q29459393 |
| P2093 | author name string | T Anh Wartel | |
| Josemund Menezes | |||
| Anand Prakash Dubey | |||
| Arun Narayan | |||
| Jugesh Chhatwal | |||
| Sharad Agarkhedkar | |||
| Satyabrata Ganguly | |||
| P2860 | cites work | The global distribution and burden of dengue | Q24628768 |
| Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | Q29616259 | ||
| Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial | Q34428943 | ||
| Efficacy of a tetravalent dengue vaccine in children in Latin America. | Q34446032 | ||
| Economic and disease burden of dengue illness in India | Q34640305 | ||
| Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010. | Q35211928 | ||
| Priming effect of dengue and yellow fever vaccination on the immunogenicity, infectivity, and safety of a tetravalent dengue vaccine in humans | Q35246126 | ||
| Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore | Q36631286 | ||
| Economic burden of dengue infections in India | Q37134806 | ||
| Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil | Q37372595 | ||
| A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand | Q37443026 | ||
| Fifty years of dengue in India | Q37987342 | ||
| Identifying protective dengue vaccines: guide to mastering an empirical process | Q38125045 | ||
| Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines | Q38931449 | ||
| Enhanced severity of secondary dengue-2 infections: death rates in 1981 and 1997 Cuban outbreaks | Q39038287 | ||
| Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. | Q40142974 | ||
| Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study | Q40231133 | ||
| Dengue fever is massively under-reported in India, hampering our response | Q40263736 | ||
| Dengue: Indian subcontinent in the line of fire. | Q40459167 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P921 | main subject | India | Q668 |
| placebo | Q269829 | ||
| Dengue virus | Q476209 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 512-8 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial | |
| P478 | volume | 12 |
| Q38738484 | A recombinant live attenuated tetravalent vaccine for the prevention of dengue |
| Q90560585 | A review of Dengvaxia®: development to deployment |
| Q97521587 | Anti-dengue Vaccines: From Development to Clinical Trials |
| Q63246360 | Dengue Situation in Bangladesh: An Epidemiological Shift in terms of Morbidity and Mortality |
| Q55046089 | Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014). |
| Q88536628 | Dengue vaccination during pregnancy - An overview of clinical trials data |
| Q58367209 | Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults |
| Q66679185 | In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment |
| Q38734455 | Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination |
| Q97540854 | Management of dengue hemorrhagic fever in a secondary level hospital in Bangladesh: A case report |
| Q26700096 | Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials |
| Q38923188 | Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease |
Search more.